10.2  0.71 (7.48%)		01-13 16:00
Open: 9.5 High: 10.2 Volume: 3,762		Pre. Close: 9.49 Low: 9.5 Market Cap: 86(M)

Short term
Mid term
Targets	6-month :	15.8	1-year :	18.83
Resists	First :	13.53	Second :	16.12
Pivot price	10.87
Supports	First :	9.32	Second :	7.76
MAs	MA(5) :	9.78	MA(20) :	11.32
	MA(100) :	13.01	MA(250) :	12.8
MACD	MACD :	-1.2	Signal :	-1.1
%K %D	K(14,3) :	9.6	D(3) :	8
RSI	RSI(14): 34.1
52-week	High :	23.98	Low :	8.85

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EXOZ ] has closed above bottom band by 33.3%. Bollinger Bands are 16.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.22 - 10.29	10.29 - 10.35
Low:	9.34 - 9.42	9.42 - 9.5
Close:	10.07 - 10.2	10.2 - 10.33

eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Tue, 13 Jan 2026
eXoZymes (NASDAQ:EXOZ) Stock Price Down 1.7% – Here’s Why - Defense World

Thu, 11 Dec 2025
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion - ACCESS Newswire

Thu, 13 Nov 2025
eXoZymes (NASDAQ: EXOZ) appoints Tyler Korman CSO, names Amy Lunzer Chief of Staff - Stock Titan

Tue, 06 May 2025
eXoZymes Launches Spin-Out, NCTx, To Unlock A Promising Compound For Gut And Liver Health - SynBioBeta

Thu, 10 Apr 2025
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - GlobeNewswire

Mon, 03 Mar 2025
Pasadena Star News - FinancialContent

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	8 (M)
Shares Float	6 (M)
Held by Insiders	71.7 (%)
Held by Institutions	0.7 (%)
Shares Short	10 (K)
Shares Short P.Month	13 (K)

EPS	-1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.63
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-99.8 %
Return on Equity (ttm)	-940.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.04
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-10.31
PEG Ratio	0
Price to Book value	15.93
Price to Sales	0
Price to Cash Flow	-8.36

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.